Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Difference in clinicopathological features due to pack-years

From: Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer

Parameters Smoker p value Pack-years p value
Yes (n = 44) No (n = 105) High (n = 43) Low (n = 106)
Age (years old)
 ≤ 56 24 (54.5%) 51 (48.6%) 0.509 24 (55.8%) 51 (48.1%) 0.398
 > 56 20 (45.5%) 54 (51.4%) 19 (44.2%) 55 (51.9%)
Tumour size (mm)
 ≤ 27.6 25 (56.8%) 50 (47.6%) 0.309 25 (58.1%) 50 (47.2%) 0.228
 > 27.6 19 (43.2%) 55 (52.4%) 18 (41.9%) 56 (52.8%)
Skin infiltration
 Negative 40 (90.9%) 94 (89.5%) 0.799 40 (93.0%) 94 (88.7%) 0.428
 Positive 4 (9.1%) 11 (10.5%) 3 (7.0%) 12 (11.3%)
Lymph node status
 Negative 18 (40.9%) 33 (31.4%) 0.269 18 (41.9%) 33 (31.1%) 0.214
 Positive 26 (59.1%) 72 (68.6%) 25 (58.1%) 73 (68.9%)
Ki67
 Negative 6 (13.6%) 17 (16.2%) 0.69 6 (14.0%) 17 (16.0%) 0.752
 Positive 38 (86.4%) 88 (83.8%)   37 (86.0%) 89 (84.0%)  
Intrinsic subtype
 HER2-enriched 22 (50.0%) 40 (38.1%) 0.181 22 (51.2%) 40 (37.7%) 0.134
 Triple-negative 22 (50.0%) 65 (61.9%) 21 (48.8%) 66 (62.3%)
ORR
 Non-responders 3 (6.8%) 8 (7.6%) 0.866 3 (7.0%) 8 (7.5%) 0.905
 Responders 41 (93.2%) 97 (92.4%) 40 (93.0%) 98 (92.5%)
pCR
 Negative 17 (38.6%) 58 (55.2%) 0.065 16 (37.2%) 59 (55.7%) 0.042
 Positive 27 (61.4%) 47 (44.8%)   27 (62.8%) 47 (44.3%)  
Recurrence
 Negative 40 (90.9%) 83 (79.0%) 0.083 39 (90.7%) 84 (79.2%) 0.096
 Positive 4 (9.1%) 22 (21.0%) 4 (9.3%) 22 (20.8%)
TILs
 Low 13 (29.6%) 45 (42.9%) 0.075 12 (27.9%) 46 (43.4%) 0.043
 High 31 (70.5%) 60 (57.1%) 31 (72.1%) 60 (56.6%)
  1. HER human epidermal growth factor receptor, ORR objective response rate, pCR pathological complete response, TILs tumour-infiltrating lymphocytes